Transmitting information to us by e-mail unilaterally does not establish an attorney-client relationship or impose an obligation on either the law firm or even the receiving lawyer to keep the transmitted information confidential. By clicking "OK", you acknowledge that we have no obligation to maintain the confidentiality of any information you submit to us unless we already represent you or unless we have agreed to receive limited confidential material/information from you as a prospective client. Thus, if you are not a client or someone we have agreed to consider as a prospective client, information you submit to us by e-mail may be disclosed to others or used against you. If you would like to discuss becoming a client, please contact one of our attorneys to arrange for a meeting or telephone conference. If you wish to disclose confidential information to a lawyer in the firm before an attorney-client relationship is established, the protections that the law firm will provide to such information from a prospective client should be discussed before such information is submitted. Thank you for your interest in Goodwin Procter.

$4.4B Health Care Co.'s Go-Public Deal (Law360)

Related Content

New Momentum for a Time-Limited Conditional Approval Pathway for Rare Disease Drugs

Four Steps to Maximize the Value of AI Innovation in Medtech

How the EU AI Act Could Affect Medtech Innovation

Alvotech and Teva Announce FDA Approval of Additional Presentation for Ustekinumab Biosimilar

Bio-Thera and Gedeon Richter Reach Exclusive Commercialization Agreement for Ustekinumab Biosimilar

NYDFS Publishes Guidance on AI-Related Cybersecurity Risks

Accord Biopharma Announces FDA Approval of IMULDOSA (ustekinumab-srlf)

Federal Circuit Denies Injunction Pending Appeal After Amgen Beat Preliminary Injunction for Biosimilar Aflibercept

US & EP Data Exclusivity: Same Name, Different Games

Scalpel AI Raises £3.8 Million in Funding

Goodwin Advises Axonis Therapeutics in $115 Million Series A Financing

Goodwin Advises ProQR on $69.8 Million Underwritten Public Offering Closing and $12.3 Million Concurrent Private Placement

Aerovate Therapeutics to Combine with Jade Biosciences in All-Stock Transaction

Goodwin Advises Septerna in $288 Million Upsized Initial Public Offering

Eight Goodwin Partners Named 2025 IAM Global Leaders

Goodwin Advises TELA on $46 Million Underwritten Public Offering of Common Stock

Life Sciences

Healthcare

Technology

Private Equity

Capital Markets

Mergers & Acquisitions

Special Purpose Acquisition Companies (SPACs)